🔗 Share this article

While the US proceeds with sweeping changes to its immunization schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on Covid vaccines throughout the global health crisis and has zeroed in on alleged fatalities after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Health officials had intended to unveil major changes to the pediatric immunization program earlier this month, bringing the US with Denmark’s national calendar, sources say – a major change that would put the US out of alignment with a large portion of the global community with no evidence for improved outcomes. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the center this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a country with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no apparent background in drug development, approval processes or management, which has been typical for former leaders of the biologics center. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “understand laws and regulations and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who led CBER have had.”

CDER has an immense portfolio at the agency, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of generic medications. There is also a biosimilars program, over-the-counter program and more, and all of those have to be supervised,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the role, which supervises over 5,000 employees. “It is a huge leadership role, if you execute it properly,” Woodcock concluded.

Response and Contentious Policies

In response to questions about Dr. Høeg's credentials and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “concerns stem from flawed assumptions”.

“Her experience is consistent with the responsibilities of her position,” the official stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial expedited therapy clearance system that allegedly worried her predecessors. “By what process are these therapies being picked for this fast-track system? Who makes the choices?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards laxer rules of all drugs, aside from vaccines.”

Established History on Immunizations

With vaccines, Dr. Høeg has a clearer, if problematic, past, critics observe. She released a study using unconfirmed public submissions to determine the incidence of heart inflammation after COVID-19 immunization. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the new federal leadership included revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she said following the vote on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of barring young men from obtaining COVID-19 vaccines.

“She is an thorough ideologue who starts off with her beliefs and tailors the evidence to fit the data in a extremely misleading, fraudulent fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other dissenters, {like|